National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Brivaracetam (Briviact®) is indicated as adjunctive therapy in the treatment of partial-onset seizures (POS) with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy.

Rapid Review

Commenced Completed Outcome
15/02/2016 22/03/2016 Full Pharmacoeconomic Evaluation Recommended at the submitted price.

The HSE has approved reimbursement following confidential price negotiations.